← Back to Clinical Trials
Recruiting Phase 2 NCT06794996
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Trial Parameters
Condition Proteinuric Kidney Disease
Sponsor Vertex Pharmaceuticals Incorporated
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 45
Sex ALL
Min Age 18 Years
Max Age 67 Years
Start Date 2025-02-04
Completion 2026-12-30
Interventions
Inaxaplin
Brief Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Eligibility Criteria
Key Inclusion Criteria: * Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay * Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening Key Exclusion Criteria: * Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants * Uncontrolled hypertension Other protocol defined Inclusion/Exclusion criteria may apply.